The same work, 27 times over.

Split the assessment: clinical vs value.

The whole design rests on a single, sharp distinction — and it's exactly the axis from last lesson. There are two very different questions inside any HTA:

• "Does this drug work better than the comparator, and how safe is it?" This is a scientific question. It's answered by reading clinical evidence, and the answer doesn't change at a national border — the data is the data. This is the relative effectiveness question.
• "Is that benefit worth what it costs us?" This is a value question — what a country's HTA process calls the appraisal. It depends on a country's willingness-to-pay threshold, its budget, its priorities, its healthcare system — all of which are national, political, and legitimately different from place to place.

The insight of the EU HTA Regulation is that these two questions have opposite natures. The first is universal and shareable — do it once. The second is local and sovereign — leave it to each country. So the Regulation splits the assessment along exactly that seam: the clinical evaluation is done jointly, at EU level, in a Joint Clinical Assessment; the value judgement, the pricing, and the reimbursement decision stay entirely national. It harmonises the half of HTA that can be harmonised, and deliberately doesn't touch the half that can't.

What the JCA is (and where it stands).

The EU HTA Regulation (Regulation (EU) 2021/2282, "HTAR") created the framework, and its centrepiece is the Joint Clinical Assessment (JCA): a single, shared, scientific assessment of a technology's relative clinical effectiveness and safety, produced once at EU level and made available to every member state. It runs in parallel with the European Medicines Agency's marketing-authorisation process — the EMA still decides whether a drug can be sold at all; the JCA addresses how it compares clinically to alternatives, for HTA purposes.

The rollout is deliberately staged, starting with the technologies where joint work adds most value:

• From 12 January 2025 — new oncology medicines and advanced therapy medicinal products (ATMPs).
• From January 2028 — orphan medicines (rare diseases).
• From 2030 — all new medicinal products.
• Selected high-risk medical devices and IVDs enter from 2026.

In its first year the system ran a modest handful of assessments (around ten), scaling up substantially thereafter. The framework applies across the EU and the EEA, with some neighbouring countries participating or observing, and it replaces the earlier project-based cooperation known as EUnetHTA with a permanent, legally grounded structure.

What the JCA deliberately is not.

This is the screen that prevents the single most common misunderstanding about the JCA — and it's a matter of design, not limitation. The JCA is defined as much by what it refuses to do as by what it does.

• It does not assess cost-effectiveness. No ICER, no threshold comparison, no economic evaluation. The JCA reports on clinical effectiveness and safety only. The moment money enters, you've left the JCA and returned to national territory.
• It makes no judgement on value, price, or reimbursement. The JCA draws no conclusion about whether the drug is "worth it," what it should cost, or whether it should be funded. It provides an objective scientific summary; the appraisal — the value judgement — is left entirely to each member state.
• It is not binding. Member states must give the JCA report "due consideration" — they have to acknowledge it, take it into account, and justify the extent to which they do or don't rely on it. But they are not obliged to adopt its conclusions. A country can reach a different clinical view, if it can reasonably justify doing so.

Put the three together and the boundary is razor-sharp. The JCA harmonises the clinical assessment — the scientific reading of the evidence. It stops precisely where appraisal begins. Value, cost-effectiveness, price, and the reimbursement decision remain, by design, sovereign national choices. The Regulation coordinated the science and left the politics of value exactly where it found it.

What's shared, what stays national.

Here are the pieces of a full health technology assessment. Sort each into where it now happens under the EU HTA Regulation: done once, jointly, at EU level (the JCA), or left to each country. The line you draw is the whole point of the Regulation.

Notice where the line falls. It doesn't split "important" from "unimportant," or "hard" from "easy." It splits what's the same everywhere (the clinical evidence) from what's legitimately different everywhere (what a country will pay, and what it decides). That's why the JCA can be genuinely shared while the decision stays genuinely national — the Regulation only pooled the part that was always going to be identical anyway.

Now you.

The PICO problem: one assessment, many questions.

Here's where the elegant theory meets a genuinely hard reality — and it's the thing every HTA practitioner working with the JCA runs into first.

Recall PICO from Module 1: an assessment's question is framed by its Population, Intervention, Comparator, and Outcomes. The trouble is that the C — the comparator — differs by country. Standard care for a given cancer isn't the same in Germany, France, and Poland; each country wants the new drug compared against its own current practice. So when a single joint assessment has to serve all member states, it can't ask just one PICO question — it has to answer everyone's. Each country submits its own PICO requirements, and after consolidation the JCA can end up with a large set of distinct PICOs to address — often ten to thirty or more for an oncology product.

Now watch the paradox bite. The manufacturer must build a single dossier that answers all of those PICOs at once — every relevant population, every national comparator, every outcome any member state asked for. And because the drug was rarely tested head-to-head against every one of those comparators, answering them demands a battery of indirect treatment comparisons (recall Module 4) — statistically demanding, evidence-hungry work, produced under a very tight timeline of roughly 90–100 days after the final PICO scope is set.

So "one assessment instead of twenty-seven" turns out to mean "one assessment that must satisfy the combined requirements of twenty-seven." The joint process removes the duplication of effort, but it cannot remove the diversity of national needs — it absorbs it into a single, larger, more complex dossier. Harmonising the process doesn't harmonise what each country wants to know.

Partial harmonisation, and why full is impossible.

Step back and the JCA reveals what it really is: partial harmonisation, by design — and the "partial" is the whole point, not a shortfall.

Could the EU go further and harmonise the whole of HTA — a single European threshold, a single European reimbursement decision? In principle, no — and not merely for political squeamishness. The value half of HTA is inseparable from things that are constitutionally national: how a country funds its health system, how big its budget is, what it's willing to trade off, what it will pay for a year of health. Setting a common willingness-to-pay threshold would mean the EU dictating how member states spend their own health budgets and rank their own priorities — a core sovereign function no member state will cede. The threshold isn't a technical parameter that happens to vary; it's a political expression of national values.

So the Regulation harmonises exactly as far as it can and no further: the objective clinical science, done once, plus a coordinated process — while price, value, and the decision stay national. It replaced the old, voluntary, project-based EUnetHTA cooperation with a permanent legal structure, forbids member states from making manufacturers resubmit the same clinical data nationally, and sets a common evidentiary base. That's a real and substantial change — even though, at the end of it, twenty-seven countries can still reach twenty-seven different decisions on the same drug, because the part that decides was always going to stay theirs.

How many things are wrong?

Why this matters for HTA

The EU HTA Regulation is reshaping how HTA evidence is produced and used across Europe, and working with it means holding its boundaries precisely:

• Know where the JCA stops. Its output is a clinical assessment — relative effectiveness and safety — and nothing more. When you see a JCA conclusion, the questions of value, cost-effectiveness, price, and reimbursement are all still open and all still national. Treating a positive JCA as an approval, or as a value verdict, misreads the entire system.
• Design evidence for the PICO storm, early. Because a JCA must answer every member state's PICO at once, the comparator and outcome diversity is the central practical challenge — often demanding indirect comparisons the pivotal trial never supported. The work of anticipating those PICOs and building the evidence to address them starts long before submission, ideally at trial-design stage.
• Expect shared science, divergent decisions — and know that's the design. The JCA gives member states a common clinical base, but they still appraise value and decide reimbursement separately. Different national verdicts on the same drug, after the same JCA, aren't a failure of harmonisation — they're exactly what a system that pooled the science and kept the values national is built to produce.

The EU HTA Regulation harmonised the one part of HTA that was always the same — the clinical science — and had the wisdom to leave alone the part that was always going to differ: what a nation decides a year of health is worth. It's coordination where coordination is possible, and sovereignty where sovereignty is unavoidable.

The EU HTA Regulation & JCA, in one breath.

• The EU HTA Regulation (HTAR) created the Joint Clinical Assessment (JCA): a single, shared, scientific assessment of a drug's relative clinical effectiveness and safety, done once at EU level (running in parallel with the EMA), so 27 countries no longer duplicate the same clinical work.
• It works by splitting HTA along the clinical-versus-value seam: the universal science is pooled at EU level; value, cost-effectiveness, price, and the reimbursement decision stay entirely national. The JCA harmonises assessment, never appraisal.
• Three boundaries define it: it does not assess cost-effectiveness, makes no reimbursement or value decision, and is not binding (states owe it "due consideration," not adoption). It rolls out in stages — oncology + ATMPs (2025) → orphan drugs (2028) → all new medicines (2030); high-risk devices from 2026 (status as of July 2026 — a fast-moving area; check official sources).
• The central practical hurdle is the PICO problem: because each country wants its own comparator, one joint assessment must answer all member states' PICOs at once (often 10–30+), demanding indirect comparisons — so it removes duplication but absorbs, rather than erases, national diversity. It's partial harmonisation — because a common threshold would mean dictating national budgets, which is politically impossible.

"One assessment, not twenty-seven" is true of the science and false of the decision. Europe pooled the reading of the evidence and kept the judgement of its worth — because the first is a fact, and the second is a choice each nation reserves for itself.

The JCA hands each country a shared clinical foundation — but it's only the start of that country's own process. What happens next, nationally, is where an assessment becomes an actual decision: the submission, the appraisal committee, the negotiation, the listing. That national reimbursement process — how a dossier becomes a "yes" — is the next lesson.